Cue Biopharma, Inc. (CUE) financial statements (2023 and earlier)

Company profile

Business Address 21 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:64,40084,90059,41039,213
Cash and cash equivalents64,37174,86644,29020,800
Short-term investments 10,00315,12018,413
Other undisclosed cash, cash equivalents, and short-term investments2931 0
Restricted cash and investments   50
Receivables3,1431,417755 
Other undisclosed current assets9261,2108601,347
Total current assets:68,46887,52761,02540,610
Noncurrent Assets
Operating lease, right-of-use asset9,8106,7745,337
Property, plant and equipment2,1122,1081,8472,781
Deposits noncurrent assets2,7212,5722,5721,013
Restricted cash and investments150150150150
Other noncurrent assets140402674809
Total noncurrent assets:14,93312,00610,5804,753
TOTAL ASSETS:83,40199,53471,60545,363
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,2114,8583,1103,823
Accounts payable2,5912,0708832,035
Accrued liabilities4,6202,7872,2271,788
Debt  4,448 
Deferred rent credit   381
Other undisclosed current liabilities5,57711,4584,0972,012
Total current liabilities:12,78816,31611,6556,217
Noncurrent Liabilities
Long-term debt and lease obligation5,1212,3691,348 
Operating lease, liability5,1212,3691,348
Other undisclosed noncurrent liabilities(5,121)(431)4,0185,175
Total noncurrent liabilities:5,1214,3065,3665,175
Total liabilities:17,90920,62217,02111,392
Stockholders' equity
Stockholders' equity attributable to parent65,49278,91154,58433,971
Common stock32302721
Additional paid in capital262,906232,159163,068105,763
Accumulated other comprehensive income (loss) 7(10)(11)
Accumulated deficit(197,446)(153,285)(108,500)(71,801)
Total stockholders' equity:65,49278,91154,58433,971
TOTAL LIABILITIES AND EQUITY:83,40199,53471,60545,363

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues14,9413,1543,4581,143
Gross profit:14,9413,1543,4581,143
Operating expenses(58,653)(48,197)(40,228)(39,839)
Operating loss:(43,712)(45,043)(36,769)(38,697)
Nonoperating income46464483541
Other nonoperating income  64165
Loss from continuing operations before income taxes:(43,666)(44,579)(36,286)(38,155)
Income tax expense(495)(206)(413)(825)
Net loss available to common stockholders, diluted:(44,161)(44,785)(36,699)(38,980)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(44,161)(44,785)(36,699)(38,980)
Other comprehensive income (loss)(7)171 
Comprehensive loss:(44,168)(44,767)(36,698)(38,980)
Other undisclosed comprehensive loss, net of tax, attributable to parent   (11)
Comprehensive loss, net of tax, attributable to parent:(44,168)(44,767)(36,698)(38,991)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: